Moderna (NASDAQ:MRNA) Now Covered by Evercore ISI

Analysts at Evercore ISI assumed coverage on shares of Moderna (NASDAQ:MRNAGet Free Report) in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm set an “in-line” rating and a $120.00 price target on the stock. Evercore ISI’s price target points to a potential downside of 4.51% from the company’s previous close.

MRNA has been the subject of several other reports. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Royal Bank of Canada increased their target price on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Oppenheimer boosted their price target on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. HSBC reissued a “reduce” rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Finally, UBS Group lifted their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $126.46.

Check Out Our Latest Research Report on MRNA

Moderna Stock Up 7.1 %

Shares of NASDAQ MRNA opened at $125.67 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The company has a market capitalization of $48.16 billion, a P/E ratio of -8.02 and a beta of 1.57. The company’s 50 day moving average price is $108.24 and its 200-day moving average price is $96.29. Moderna has a 52-week low of $62.55 and a 52-week high of $142.79.

Moderna (NASDAQ:MRNAGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same period in the previous year, the company posted $0.19 earnings per share. The firm’s revenue for the quarter was down 91.0% on a year-over-year basis. Equities analysts forecast that Moderna will post -7.53 earnings per share for the current year.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the sale, the director now directly owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. In the last three months, insiders have sold 155,209 shares of company stock valued at $16,678,621. Corporate insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently modified their holdings of MRNA. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna in the fourth quarter valued at $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Cedar Wealth Management LLC increased its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Westside Investment Management Inc. purchased a new stake in Moderna in the first quarter worth about $32,000. Finally, Rise Advisors LLC boosted its position in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.